Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy: a Claims-based Cohort Study From 2015 to 2020

• by Daniel J Rogers, Lingyu Zhao, Duna Zhan, Xianyan Chen, Martin Krsak, Andrés F Henao-Martínez, Daniel B Chastain

• June 2, 2025

Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies

• by Lin Zhu, Lora N. Magaldi, Indrani A. Wagh, Eliza R. Ennis, Marissa B. Reitsma, Danica E. Kuncio, Eman Addish, Sandy R. Varghese, Nathan W. Furukawa, Amanda A. Honeycutt, Yijie Chen, Benjamin P. Linas, Joshua A. Salomon

• May 1, 2026

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.

• by Kathryn Wighton

• April 16, 2026

• 3 min

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

• by Kathryn Wighton

• May 29, 2026

• 3 min